LT3122775T - Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui - Google Patents

Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui

Info

Publication number: LT3122775T
Authority: LT; Lithuania
Prior art keywords: cancer; gdf; monoclonal antibodies; antibodies against; canceration
Prior art date: 2014-03-26

Application number

LTEP15712629.3T

Other languages

English (en)

Inventor

Jörg WISCHHUSEN

Markus JUNKER

Tina SCHÄFER

Dirk PÜHRINGER

Original Assignee

Julius-Maximilians-Universität Würzburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-26

Filing date

2015-03-26

Publication date

2020-02-10

2014-03-26 Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en

2014-03-26 Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en

2015-03-26 Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg

2020-02-10 Publication of LT3122775T publication Critical patent/LT3122775T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Compositions Of Macromolecular Compounds (AREA)
Cosmetics (AREA)

LTEP15712629.3T 2014-03-26 2015-03-26 Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui LT3122775T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1405475.3A GB2524552B (en)	2014-03-26	2014-03-26	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405477.9A GB2524553C (en)	2014-03-26	2014-03-26	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
PCT/EP2015/056654 WO2015144855A1 (en)	2014-03-26	2015-03-26	Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (1)

Publication Number	Publication Date
LT3122775T true LT3122775T (lt)	2020-02-10

Family

ID=52745885

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP19205321.3T LT3653644T (lt)	2014-03-26	2015-03-26	Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
LTEP15712629.3T LT3122775T (lt)	2014-03-26	2015-03-26	Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP19205321.3T LT3653644T (lt)	2014-03-26	2015-03-26	Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą

Country Status (22)

Country	Link
US (6)	US20170204174A1 (lt)
EP (3)	EP3122775B1 (lt)
JP (3)	JP6865585B2 (lt)
KR (1)	KR102520978B1 (lt)
CN (1)	CN106536553B (lt)
AU (2)	AU2015238264B2 (lt)
BR (1)	BR122023027559A2 (lt)
CY (1)	CY1122456T1 (lt)
DK (2)	DK3653644T5 (lt)
ES (2)	ES2763859T3 (lt)
FI (1)	FI3653644T3 (lt)
HR (2)	HRP20231514T1 (lt)
HU (2)	HUE047398T2 (lt)
IL (2)	IL248038B (lt)
LT (2)	LT3653644T (lt)
NZ (1)	NZ724649A (lt)
PL (2)	PL3653644T3 (lt)
PT (2)	PT3122775T (lt)
RS (1)	RS59700B1 (lt)
SI (1)	SI3122775T1 (lt)
SM (1)	SMT202000064T1 (lt)
WO (1)	WO2015144855A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3653644T3 (pl)	2014-03-26	2024-03-04	Julius-Maximilians-Universität Würzburg	Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów
PL3197493T3 (pl)	2014-09-25	2021-08-23	Aveo Pharmaceuticals Inc.	Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
EA201890850A1 (ru) *	2015-10-02	2018-09-28	Юлиус-Максимилианс-Универзитет Вюрцбург	Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
ES2968226T3 (es) *	2015-10-02	2024-05-08	Univ Wuerzburg J Maximilians	GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
GB201517528D0 (en) *	2015-10-02	2015-11-18	Julius Maximillians Universitãt Würzburg	GDF-15 as a diagnosis marker for melanoma
WO2017189724A1 (en) *	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
BR112019000220A2 (pt) *	2016-07-06	2019-04-24	National Research Council Of Canada	anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos
AU2017342028A1 (en) *	2016-10-12	2019-04-11	Janssen Biotech, Inc.	Methods for screening for modulators of GDF15-like biological activity
JP7134960B2 (ja) *	2016-12-06	2022-09-12	セントビンセンツホスピタルシドニーリミテッド	肥満及び摂食障害の治療
EP3841121A2 (en) *	2018-08-20	2021-06-30	Pfizer Inc.	Anti-gdf15 antibodies, compositions and methods of use
IL302646A (en) *	2020-11-10	2023-07-01	Catalym Gmbh	Anti-GDF15 antibody and dosage regimen for cancer treatment
JP2024511853A (ja)	2021-03-31	2024-03-15	カイマブ・リミテッド	Ｇｄｆ１５シグナル伝達の治療的阻害剤
EP4384545A1 (en)	2021-08-10	2024-06-19	BYOMass Inc.	Anti-gdf15 antibodies, compositions and uses thereof
EP4452316A1 (en)	2021-12-22	2024-10-30	BYOMass Inc.	Targeting gdf15-gfral pathway
KR20240134385A (ko) *	2022-01-26	2024-09-09	윤난 베이야오 그룹 컴파니 리미티드	항-성장 분화 인자 15의 항체 분자 및 그의 응용
US20250326828A1 (en)	2022-05-09	2025-10-23	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies Specifically Recognizing Gdf15 and Uses Thereof
CN116462757A (zh) *	2023-03-24	2023-07-21	科兴生物制药股份有限公司	Gdf15的单域抗体及其应用
CN118878677A (zh) *	2024-09-29	2024-11-01	江苏凯基生物技术股份有限公司	一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6455677B1 (en) *	1998-04-30	2002-09-24	Boehringer Ingelheim International Gmbh	FAPα-specific antibody with improved producibility
EP0953639A1 (en) *	1998-04-30	1999-11-03	Boehringer Ingelheim International GmbH	FAPalpha-specific antibody with improved producibility
US6465181B2 (en)	1999-03-25	2002-10-15	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
DE60032355T2 (de)	1999-05-17	2007-04-26	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh	NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
US7141661B2 (en)	2000-09-08	2006-11-28	The United States Of America As Represented By The Department Of Health And Human Services	Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
RU2401277C2 (ru) *	2004-01-07	2010-10-10	Чирон Корпорейшн	Не мышиное анти-m-csf-антитело (варианты), его получение и использование
DK2441466T3 (da) *	2004-04-13	2014-10-27	St Vincents Hosp Sydney	MIC-1-inhiberende middel
CA2694863A1 (en) *	2007-08-16	2009-02-19	Garvan Institute Of Medical Research	Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
WO2009046495A1 (en) *	2007-10-09	2009-04-16	St Vincent's Hospital Sydney Limited	A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
NZ591484A (en)	2008-09-29	2012-09-28	Roche Glycart Ag	Antibodies against human il 17 and uses thereof
US20120309697A1 (en)	2009-10-28	2012-12-06	Samuel Norbert Breit	Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) *	2010-03-03	2015-12-15	Detroit R & D, Inc.	Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
PH12013500974A1 (en)	2010-11-17	2013-07-08	Chugai Pharmaceutical Co Ltd	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
CN102321173B (zh)	2011-08-12	2013-04-03	中国医学科学院肿瘤研究所	人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en)	2011-08-31	2013-03-06	VTU Holding GmbH	Protein expression
BR112014018575A2 (pt)	2012-01-26	2017-07-04	Amgen Inc	polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP3590537A1 (en) *	2012-09-26	2020-01-08	Julius-Maximilians-Universität Würzburg	Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
JP6758832B2 (ja) *	2012-12-21	2020-09-30	アベオファーマシューティカルズ，インコーポレイテッド	抗ｇｄｆ１５抗体
PL3653644T3 (pl)	2014-03-26	2024-03-04	Julius-Maximilians-Universität Würzburg	Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów

2015
- 2015-03-26 PL PL19205321.3T patent/PL3653644T3/pl unknown
- 2015-03-26 ES ES15712629T patent/ES2763859T3/es active Active
- 2015-03-26 BR BR122023027559-4A patent/BR122023027559A2/pt not_active Application Discontinuation
- 2015-03-26 FI FIEP19205321.3T patent/FI3653644T3/fi active
- 2015-03-26 SM SM20200064T patent/SMT202000064T1/it unknown
- 2015-03-26 PT PT157126293T patent/PT3122775T/pt unknown
- 2015-03-26 JP JP2016559286A patent/JP6865585B2/ja active Active
- 2015-03-26 HU HUE15712629A patent/HUE047398T2/hu unknown
- 2015-03-26 HR HRP20231514TT patent/HRP20231514T1/hr unknown
- 2015-03-26 NZ NZ724649A patent/NZ724649A/en unknown
- 2015-03-26 AU AU2015238264A patent/AU2015238264B2/en active Active
- 2015-03-26 EP EP15712629.3A patent/EP3122775B1/en active Active
- 2015-03-26 ES ES19205321T patent/ES2965626T3/es active Active
- 2015-03-26 CN CN201580027932.8A patent/CN106536553B/zh active Active
- 2015-03-26 DK DK19205321.3T patent/DK3653644T5/da active
- 2015-03-26 SI SI201531059T patent/SI3122775T1/sl unknown
- 2015-03-26 EP EP19205321.3A patent/EP3653644B1/en active Active
- 2015-03-26 HU HUE19205321A patent/HUE064573T2/hu unknown
- 2015-03-26 LT LTEP19205321.3T patent/LT3653644T/lt unknown
- 2015-03-26 RS RS20191652A patent/RS59700B1/sr unknown
- 2015-03-26 PL PL15712629T patent/PL3122775T3/pl unknown
- 2015-03-26 WO PCT/EP2015/056654 patent/WO2015144855A1/en not_active Ceased
- 2015-03-26 DK DK15712629.3T patent/DK3122775T3/da active
- 2015-03-26 KR KR1020167029710A patent/KR102520978B1/ko active Active
- 2015-03-26 US US15/128,604 patent/US20170204174A1/en not_active Abandoned
- 2015-03-26 LT LTEP15712629.3T patent/LT3122775T/lt unknown
- 2015-03-26 PT PT192053213T patent/PT3653644T/pt unknown
- 2015-03-26 EP EP23203704.4A patent/EP4316596A3/en active Pending
- 2015-03-26 HR HRP20200034TT patent/HRP20200034T1/hr unknown
2016
- 2016-09-26 IL IL248038A patent/IL248038B/en active IP Right Grant
2018
- 2018-03-05 US US15/912,358 patent/US10604565B2/en active Active
2020
- 2020-01-08 CY CY20201100008T patent/CY1122456T1/el unknown
- 2020-02-19 US US16/794,406 patent/US11760795B2/en active Active
- 2020-02-19 US US16/794,401 patent/US11634482B2/en active Active
- 2020-07-30 IL IL276405A patent/IL276405B/en unknown
- 2020-10-28 AU AU2020260440A patent/AU2020260440B2/en active Active
2021
- 2021-04-06 JP JP2021064572A patent/JP7607498B2/ja active Active
2023
- 2023-04-06 JP JP2023062338A patent/JP2023098966A/ja not_active Withdrawn
- 2023-08-02 US US18/364,173 patent/US20230382987A1/en not_active Abandoned
2025
- 2025-06-13 US US19/237,241 patent/US20260008841A1/en active Pending

Also Published As

Publication number	Publication date
AU2020260440B2 (en)	2024-03-21
EP3122775B1 (en)	2019-11-13
PL3653644T3 (pl)	2024-03-04
BR112016022013A2 (pt)	2017-10-31
DK3653644T5 (da)	2024-08-26
SI3122775T1 (sl)	2020-02-28
US11634482B2 (en)	2023-04-25
US20180298091A1 (en)	2018-10-18
JP6865585B2 (ja)	2021-04-28
US11760795B2 (en)	2023-09-19
HRP20200034T1 (hr)	2020-03-20
JP2023098966A (ja)	2023-07-11
US10604565B2 (en)	2020-03-31
EP3653644B1 (en)	2023-11-15
IL276405B (en)	2021-07-29
US20200308264A1 (en)	2020-10-01
US20230382987A1 (en)	2023-11-30
JP7607498B2 (ja)	2024-12-27
WO2015144855A1 (en)	2015-10-01
PT3122775T (pt)	2019-12-26
ES2763859T3 (es)	2020-06-01
NZ724649A (en)	2022-07-01
RS59700B1 (sr)	2020-01-31
HUE047398T2 (hu)	2020-04-28
AU2015238264B2 (en)	2020-09-03
CN106536553A (zh)	2017-03-22
US20170204174A1 (en)	2017-07-20
BR122023027559A2 (pt)	2024-01-30
DK3653644T3 (da)	2023-12-18
FI3653644T3 (fi)	2023-12-12
KR102520978B1 (ko)	2023-04-11
CY1122456T1 (el)	2021-01-27
AU2020260440A1 (en)	2020-11-26
LT3653644T (lt)	2024-01-25
JP2017508475A (ja)	2017-03-30
PT3653644T (pt)	2023-12-19
CA2943694A1 (en)	2015-10-01
US20200308265A1 (en)	2020-10-01
JP2021119138A (ja)	2021-08-12
AU2015238264A1 (en)	2016-10-20
US20260008841A1 (en)	2026-01-08
HUE064573T2 (hu)	2024-03-28
ES2965626T3 (es)	2024-04-16
IL248038A0 (en)	2016-11-30
EP3122775A1 (en)	2017-02-01
IL248038B (en)	2020-08-31
KR20160139005A (ko)	2016-12-06
EP4316596A3 (en)	2024-04-17
SMT202000064T1 (it)	2020-03-13
DK3122775T3 (da)	2020-02-03
EP3653644A1 (en)	2020-05-20
PL3122775T3 (pl)	2020-05-18
IL276405A (en)	2020-09-30
HRP20231514T1 (hr)	2024-03-01
CN106536553B (zh)	2021-03-12
EP4316596A2 (en)	2024-02-07

Publication	Publication Date	Title
LT3122775T (lt)	2020-02-10	Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui
IL262092A (en)	2018-11-29	Humanized anti-pacap antibodies and uses thereof
IL270596B2 (en)	2026-01-01	Antibodies containing heavy constant regions are adapted for use in cancer therapy
IL256687B (en)	2022-02-01	Isolated tau-binding antibody and its use in treatment and diagnosis
LT3274370T (lt)	2020-02-10	Antikūnai prieš ceacam6 ir jų panaudojimas
LT3353212T (lt)	2021-12-27	Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
LT3191135T (lt)	2020-11-25	Anti-her2 antikūnai ir imunokonjugatai
LT3126388T (lt)	2019-08-26	Antikūnai prieš egfrviii ir jų panaudojimo būdai
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
LT3532499T (lt)	2021-08-10	Antikūnai prieš il-33 ir jų panaudojimas
IL258980A (en)	2018-07-31	Preparation of bispecific antigens and their use in cancer
LT4339615T (lt)	2025-12-10	Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
PL3280440T3 (pl)	2023-06-19	Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
DK3114141T3 (da)	2020-08-10	Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
DK3114140T3 (da)	2019-06-03	Insulinlignende vækstfaktor 1-receptorspecifikke antistoffer og anvendelser deraf
ZA201807132B (en)	2021-05-26	Humanized anti-basigin antibodies and the use thereof
ZA202000851B (en)	2021-08-25	Antibodies useful in cancer diagnosis
IL258515A (en)	2018-05-31	Methods of treatment using anti-il-17a/f antibodies
IL258924A (en)	2018-06-28	Humanized anti-dkk2 antibody and uses thereof
IL250507A0 (en)	2017-03-30	Anti-ck8 antibodies for use in cancer therapy
EP3095796A4 (en)	2017-11-22	Anti-human probdnf monoclonal antibody, and uses thereof in pains
GB201405477D0 (en)	2014-05-07	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer cachexia
LT3313528T (lt)	2021-10-11	Imunoterapinės dozavimo schemos, apimančios pomalidomidą ir anti-cs1 antikūną, skirtos vėžio gydymui
GB2524552B (en)	2017-07-12	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer